Latest Technology Transfer News

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

NeuRizer has secured agreements worth AUD$12.7 million with Reliance Industries, offering a potential funding bridge for its coal-gasification technology. But the company’s FY2025 accounts show a larger loss, just $183,666 in year-end cash and a material dependence on continued funding and creditor support.

Adisyn has moved closer to commercialising its graphene platform after independently verified sub-300°C deposition, a US patent allowance and a new defence technology arm. The progress came alongside a A$7.83 million statutory loss, A$4.47 million in operating cash outflows and a heavily judgement-based A$42.1 million technology asset.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.

NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

Nodestream has advanced its defence strategy with key leadership hires, a $6.5 million capital raise, and fresh product launches, while expanding its footprint in the US and European markets.

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.